Medical Devices US

US Endoscopic Bariatric Therapies Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $278.8 Mn Placeholder estimate
Estimate 2025 $307.6 Mn 40.9% of the global market
Projected 2034 $743.2 Mn 141.6% Adds $435.6 Mn over 9 forecast years
CAGR 2025–2034 10.3% Faster than 81% of 180 Medical Devices markets here
Key players 5
  • US is 40.86% of the global market.
  • In North America, the largest is US (this report) at $307.6 Mn.
  • Fastest growing: Canada at 12.3% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$435.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Endoscopic Bariatric Therapies Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $278.8 Mn — —
2025 (base) $307.6 Mn +$28.7 Mn —
2026 (forecast) $339.2 Mn +$31.7 Mn +10.3%
2027 (forecast) $374.2 Mn +$34.9 Mn +21.7%
2028 (forecast) $412.7 Mn +$38.5 Mn +34.2%
2029 (forecast) $455.2 Mn +$42.5 Mn +48%
2030 (forecast) $502.1 Mn +$46.9 Mn +63.3%
2031 (forecast) $553.8 Mn +$51.7 Mn +80.1%
2032 (forecast) $610.9 Mn +$57.0 Mn +98.6%
2033 (forecast) $673.8 Mn +$62.9 Mn +119.1%
2034 (forecast) $743.2 Mn +$69.4 Mn +141.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Endoscopic Bariatric Therapies Market Analysis at a glance
Market size, 2025$307.6 Mn placeholder estimate
Forecast, 2034$743.2 Mn placeholder estimate
Growth (CAGR), 2025–203410.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProcedure, product and end user (see all)
Key playersBoston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics, Olympus Corporation (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials19 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Endoscopic Bariatric Therapies Market Analysis Executive Summary

Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.

Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).

Bar chart: US Endoscopic Bariatric Therapies market size, 2024–2034, placeholder estimates. $278.8 Mn in 2024, $307.6 Mn in 2025 and $743.2 Mn in 2034, 10.3% CAGR.
US Endoscopic Bariatric Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Endoscopic Bariatric Therapies Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Endoscopic Bariatric Therapies Market in the US

The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Endoscopic Bariatric Therapies Market in the US

Endoscopic Bariatric Therapies in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 19 studies on Endoscopic Bariatric Therapies that are recruiting, active or about to start in the US.⁠[3] Obesity (adults): 41.0% of adults in 2024, the latest WHO figure for the US.⁠[4]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Endoscopic Bariatric Therapies right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Endoscopic Bariatric Therapies in context

The US compared

  • Obesity (adults): 41.0% of adults (2024). World: 16.2% of adults (2024).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Endoscopic Bariatric Therapies market in the US?
Placeholder estimate: about $307.6 Mn in 2025, rising to about $743.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Endoscopic Bariatric Therapies market in the US growing?
Placeholder estimate: about 10.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Endoscopic Bariatric Therapies market report cover?
The report splits the market by procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon, Duodenal Mucosal Resurfacing, Aspiration Therapy), product (Suturing Systems, Balloons, Liners) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Endoscopic Bariatric Therapies market?
Key players include Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics and Olympus Corporation.
What is driving the Endoscopic Bariatric Therapies market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market.
Who regulates Endoscopic Bariatric Therapies in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Endoscopic Bariatric Therapies are running in the US?
19 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Obesity (adults): 41.0% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on obesity and diabetes

See the topic